Loading...
XKRX030000
Market cap1.31bUSD
Dec 24, Last price  
18,690.00KRW
1D
-0.11%
1Q
1.96%
Jan 2017
19.05%
Name

Cheil Worldwide Inc

Chart & Performance

D1W1MN
XKRX:030000 chart
P/E
10.11
P/S
0.46
EPS
1,849.37
Div Yield, %
6.20%
Shrs. gr., 5y
—
Rev. gr., 5y
3.54%
Revenues
4.14t
-2.71%
694,685,148,0001,173,496,790,0001,169,390,650,0001,344,516,085,0001,758,178,413,1502,365,019,210,8102,709,281,436,3802,666,255,721,5702,806,713,644,1603,232,593,889,3603,374,986,899,1803,477,880,993,8303,421,672,988,2302,747,921,881,0203,325,712,307,5204,253,367,260,0004,138,274,796,030
Net income
187.30b
-3.32%
59,818,978,00086,691,935,00091,629,522,000103,467,820,00093,313,720,00093,651,708,00098,540,230,700101,604,521,74079,514,267,81088,263,165,590127,153,226,530129,712,696,670138,055,156,770157,399,949,860165,485,251,450193,731,654,300187,301,872,830
CFO
266.70b
+44.82%
50,058,181,000196,384,008,00049,337,880,000-19,337,217,000144,587,874,39091,241,087,140-66,212,477,49055,909,773,950102,393,207,950101,351,735,63039,090,197,990224,014,016,080200,015,098,570219,474,826,500249,513,810,060184,163,142,560266,698,725,630
Dividend
Dec 27, 20231110 KRW/sh
Earnings
Jan 28, 2025

Profile

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
URL
https://us.cheil.com/?languages=en®ionNm=USA
IPO date
Mar 03, 1998
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,138,274,796
-2.71%
4,253,367,260
27.89%
3,325,712,308
21.03%
Cost of revenue
2,827,398,812
2,984,296,646
2,252,426,756
Unusual Expense (Income)
NOPBT
1,310,875,984
1,269,070,614
1,073,285,551
NOPBT Margin
31.68%
29.84%
32.27%
Operating Taxes
94,701,074
104,600,606
92,031,140
Tax Rate
7.22%
8.24%
8.57%
NOPAT
1,216,174,910
1,164,470,008
981,254,412
Net income
187,301,873
-3.32%
193,731,654
17.07%
165,485,251
5.14%
Dividends
(117,410,333)
(100,265,938)
(89,324,926)
Dividend yield
6.09%
4.30%
3.86%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
55,280,888
71,370,025
68,176,409
Long-term debt
290,137,344
307,683,710
328,186,595
Deferred revenue
380,000
8,075,300
Other long-term liabilities
99,279,190
34,556,353
29,062,434
Net debt
(425,400,610)
(258,856,367)
(173,923,295)
Cash flow
Cash from operating activities
266,698,726
184,163,143
249,513,810
CAPEX
(26,189,270)
(22,290,308)
(16,040,089)
Cash from investing activities
(7,489,351)
16,405,679
32,947,492
Cash from financing activities
(192,340,326)
(163,263,010)
(148,604,495)
FCF
1,120,876,779
1,070,245,460
927,520,012
Balance
Cash
690,966,380
632,251,961
657,788,619
Long term investments
79,852,462
5,658,142
(87,502,320)
Excess cash
563,905,102
425,241,740
404,000,683
Stockholders' equity
1,456,629,701
2,145,796,185
2,079,522,978
Invested Capital
1,005,846,960
962,806,610
886,302,785
ROIC
123.55%
125.95%
111.61%
ROCE
83.51%
89.22%
82.09%
EV
Common stock shares outstanding
101,279
101,279
101,279
Price
19,030.00
-17.44%
23,050.00
0.88%
22,850.00
10.92%
Market cap
1,927,334,137
-17.44%
2,334,474,611
0.88%
2,314,218,866
10.92%
EV
1,513,139,096
2,085,006,166
2,150,420,706
EBITDA
1,385,858,957
1,342,605,149
1,143,970,644
EV/EBITDA
1.09
1.55
1.88
Interest
10,904,483
6,925,018
6,821,057
Interest/NOPBT
0.83%
0.55%
0.64%